Research programme: bispecific antibody macrophage engagers - Elpiscience Biopharmaceuticals
Alternative Names: BiME® programLatest Information Update: 21 Jun 2024
At a glance
- Originator Elpiscience Biopharmaceuticals
- Class Antineoplastics; Bispecific antibodies; Immunoglobulin fragments; Immunotherapies
- Mechanism of Action Macrophage stimulants; SIRPA protein inhibitors; Tumour associated macrophage modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 05 Apr 2024 Preclinical trials in Solid tumours in China (Parenteral), prior to April 2024
- 05 Apr 2024 Pharmacodynamics and adverse event data from a preclinical trial in Solid tumours presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 27 Mar 2024 Research programme: anticancer bispecific antibody therapeutics - Elpiscience Biopharmaceuticals is available for licensing as of 27 Mar 2024. https://www.elpiscience.com/partnering#partneringstrategy